GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma.
Soledad Gallego MelconD BernabeuM Garrido-PontnouG GuillenN HindiA Juan-RibellesC MárquezC MataJ OrcajoG RamírezM RamosC RomagosaD RuanoP RubioR VergésC Valverdenull nullPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm.
Keyphrases
- pet ct
- locally advanced
- end stage renal disease
- contrast enhanced
- magnetic resonance imaging
- small cell lung cancer
- positron emission tomography
- newly diagnosed
- young adults
- early stage
- minimally invasive
- high resolution
- radiation therapy
- risk factors
- prognostic factors
- peritoneal dialysis
- acute coronary syndrome
- image quality
- rectal cancer
- atrial fibrillation
- replacement therapy
- high grade
- fluorescence imaging